Jefferies downgrades Incyte stock rating on patent cliff concerns

#Jefferies #Incyte #stock rating #downgrade #patent cliff #pharmaceutical #revenue risk

Jefferies downgraded Incyte's stock rating due to patent expiration concerns
The downgrade reflects worries about future revenue as key patents near expiry
Patent cliffs threaten Incyte's ability to maintain current financial performance
Analysts are cautious about the company's growth prospects post-patent loss

Stock Downgrade, Patent Risk

No entity connections available yet for this article.

}